Tissue Plasminogen Activator
Vitrectomy without tissue plasminogen activator effective for submacular hemorrhage
NEW YORK — Vitrectomy using balanced saline solution without tissue plasminogen activator is effective for displacement of thick submacular hemorrhage, according to a speaker here.
Man presents with dark spot in peripheral vision
A 62-year-old man presented to the New England Eye Center comprehensive ophthalmology clinic for an urgent evaluation of a black shadow in the inferotemporal field of his left eye that started suddenly 4 days prior while he was sitting.
Shorter door-to-needle times improve long-term outcomes in ischemic stroke
Shorter door-to-needle times lowered all-cause mortality and all-cause readmission at 1 year in patients aged at least 65 years with acute ischemic stroke treated with tissue plasminogen activator, researchers found.
Aspiration mechanical thrombectomy meets safety, efficacy endpoints for acute PE
LAS VEGAS — In the EXTRACT-PE trial, an aspiration mechanical thrombectomy device was safe and effective among patients with acute pulmonary embolism, researchers reported at VIVA 19.
Euretina allocates funds to research management of submacular hemorrhage in wet AMD
PARIS — Partnering with Fight for Sight, the European Society of Retina Specialists will award a 2 million euros grant to a research project addressing the best treatment option for submacular hemorrhage secondary to wet age-related macular degeneration.
Part of the Healio Network
Fibrinolytic Therapy (Thrombolytic Therapy) Topic Review
Fibrinolytic therapy, also known as thrombolytic therapy, is used to lyse acute blood clots by activating plasminogen, resulting in the formation of plasmin, which cleaves the fibrin cross-links causing thrombus breakdown.